CIK 0001811063 · Non-accelerated filer<br>Smaller reporting company
Nuvation Bio Inc.
Sign in to watch- Ticker
- NUVB
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 850862255
- Phone
- 332-208-6102
- Business address
- 1 PENNSYLVANIA PLAZA, SUITE 3805, NEW YORK, NY, 10019
- Former names
- Panacea Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $709,240
- in 1 filing, $709K under 10b5-1 plans
Net −$709,240. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-19 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +100,000 | $1.87 | $187K | 100,000 |
| 2026-08-19 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −100,000 | $7.09 | $709K | 0 |
| 2026-08-19 | Hattersley Gary CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100,000 | 400,000 | ||
| 2026-07-15 | Sauvage Philippe Chief Financial Officer | Option exercise | +39,999 | $2.17 | $87K | 54,130 |
| 2026-07-15 | Sauvage Philippe Chief Financial Officer | Option exercise | +1 | $1.97 | $2 | 54,131 |
| 2026-07-15 | Sauvage Philippe Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −39,999 | 662,333 | ||
| 2026-07-15 | Sauvage Philippe Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −1 | 499,999 | ||
| 2026-06-23 | Sauvage Philippe Chief Financial Officer | Option exercise 10b5-1 | +47,668 | $2.17 | $103K | 60,341 |
| 2026-06-23 | Sauvage Philippe Chief Financial Officer | Sale 10b5-1 | −47,668 | $6.01 | $286K | 12,673 |
| 2026-06-23 | Sauvage Philippe Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −47,668 | 702,332 | ||
| 2026-06-23 | Markel Stacy CHIEF PEOPLE OFFICER | Option exercise 10b5-1 | +90,380 | $1.87 | $169K | 122,971 |
| 2026-06-23 | Markel Stacy CHIEF PEOPLE OFFICER | Option exercise 10b5-1 | +34,620 | $1.74 | $60K | 157,591 |
| 2026-06-23 | Markel Stacy CHIEF PEOPLE OFFICER | Sale 10b5-1 | −125,000 | $6.03 | $753K | 32,591 |
| 2026-06-23 | Markel Stacy CHIEF PEOPLE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −90,380 | 409,620 | ||
| 2026-06-23 | Markel Stacy CHIEF PEOPLE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −34,620 | 220,190 | ||
| 2026-06-23 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise 10b5-1 | +63,000 | $2.93 | $185K | 116,000 |
| 2026-06-23 | Wentworth Kerry CHIEF REGULATORY OFFICER | Sale 10b5-1 | −63,000 | $6.02 | $379K | 53,000 |
| 2026-06-23 | Wentworth Kerry CHIEF REGULATORY OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −63,000 | 152,250 | ||
| 2026-06-09 | Mashal Robert Director | Purchase | +25,000 | $4.73 | $118K | 225,000 |
| 2026-05-21 | Mashal Robert Director | Grant or award · Stock Option (Right to Buy) | +123,397 | 123,397 |
Page 1 of 15 · 291 trades